Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rheault, Michelle
AFFINITY, NCT04573920: Atrasentan in Patients With Proteinuric Glomerular Diseases	Active, not recruiting	2	103	Europe, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627	Novartis Pharmaceuticals	IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy	07/24	07/26
NCT03763643 / 2013-002651-15: PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant	Recruiting	1	60	US	Rituximab, Plasmapheresis	University of Minnesota, United States Department of Defense	Focal Segmental Glomerulosclerosis	08/25	12/26
NCT04075656: UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)	Active, not recruiting	N/A	60	US	Standard of Care, UrApp	Emory University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Idiopathic Nephrotic Syndrome	11/25	11/25
NCT02235857: Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children	Recruiting	N/A	35	US	LIPOSORBER® LA-15 System, LDL apheresis, LDL adsorption, dextran sulfate column	Kaneka Medical America LLC	Focal Segmental Glomerulosclerosis	05/26	07/28
ASTOR, NCT00481130: Alport Syndrome Treatments and Outcomes Registry	Recruiting	N/A	1000	US		University of Minnesota	Alport Syndrome	01/30	01/30